Plato Investment Management Ltd Buys Shares of 1,799 Axon Enterprise, Inc. (NASDAQ:AXON)

Plato Investment Management Ltd purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,799 shares of the biotechnology company’s stock, valued at approximately $529,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Norges Bank acquired a new position in Axon Enterprise in the fourth quarter valued at about $195,406,000. Motley Fool Asset Management LLC increased its stake in shares of Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after acquiring an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at approximately $81,630,000. Vanguard Group Inc. boosted its stake in Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock worth $2,547,878,000 after acquiring an additional 212,401 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Axon Enterprise by 110.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock valued at $71,302,000 after purchasing an additional 144,568 shares during the period. 79.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AXON shares. JMP Securities lifted their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price objective on shares of Axon Enterprise in a research report on Wednesday, August 7th. Bank of America started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Robert W. Baird lifted their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Barclays upped their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Stock Performance

AXON opened at $379.61 on Monday. The business’s 50-day simple moving average is $338.92 and its 200 day simple moving average is $314.68. Axon Enterprise, Inc. has a 52-week low of $189.12 and a 52-week high of $385.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a market capitalization of $28.69 billion, a PE ratio of 111.00, a PEG ratio of 10.30 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business’s revenue was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.80 EPS. As a group, sell-side analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the sale, the president now directly owns 228,166 shares in the company, valued at approximately $82,103,253.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, President Joshua Isner sold 25,811 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the transaction, the president now directly owns 228,166 shares of the company’s stock, valued at approximately $82,103,253.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the completion of the sale, the director now owns 7,379 shares in the company, valued at approximately $2,752,588.37. The disclosure for this sale can be found here. Insiders have sold 316,981 shares of company stock worth $115,281,744 in the last ninety days. Insiders own 6.10% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.